
Novavax Inc
NVAXHealthcare|Biotechnology|USA
$9.33
-0.07 (-0.74%)
Earnings Power
$97.87
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
387.27,
259.13,
348.64,
404.87,
385.1
],
"ebit_estimate": [
-93.19,
-23.18,
80.37,
232.88,
214.6
],
"ebitda_estimate": [
-71.01,
-42.12,
-25.43,
null,
null
],
"net_income_estimate": [
-82.59,
-20,
75.66,
199.94,
165.8
],
"per_share_eps_estimate": [
-0.46,
-0.07,
0.72,
1.18,
0.98
],
"eps_nri_estimate": [
-0.46,
-0.19,
0.55,
0.85,
0.98
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
-3.51,
-3.67,
null,
null,
null
],
"pretax_income_estimate": [
-91.69,
-33.97,
88.41,
244.05,
188.45
],
"operating_cash_flow_per_share_estimate": [
-0.15,
-0.95,
null,
null,
null
],
"roa_estimate": [
0.1,
-16.2,
null,
null,
null
],
"roe_estimate": [
-0.6,
62,
null,
null,
null
],
"gross_margin_estimate": [
87.5,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-24.49,
-155.11,
null,
null,
null
],
"pettm_estimate": [
0,
0,
12.96,
7.93,
9.52
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "-32.38",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": -32.38,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
51.1,
99.61,
92.69,
15.31,
22.63,
261.59,
133.43
],
"ebit_estimate": [
-68.54,
-15.16,
16.75,
-67.35,
-61.75,
181.87,
54.58
],
"ebitda_estimate": [
-73.83,
11.16,
21.99,
null,
null,
null,
null
],
"net_income_estimate": [
-67.02,
-14.97,
14.85,
-52.13,
-37.41,
75.83,
23.18
],
"per_share_eps_estimate": [
-0.39,
-0.12,
0.15,
-0.32,
-0.23,
0.45,
0.14
],
"eps_nri_estimate": [
-0.41,
-0.09,
0.09,
-0.32,
-0.23,
0.45,
0.14
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-67.76,
-17.85,
-28.78,
-59.61,
-49.81,
187.75,
66.95
],
"operating_cash_flow_per_share_estimate": [
1.04,
3.46,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
169.81,
564.94,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
155.5,
207.33,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "-32.38",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": -32.38,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}